BioPharma Drug Discovery
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast in Lower-Risk Myelodysplastic Syndromes
Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 Ha...
June 17, 2026 | News
Pelago Bioscience Acquires RG Discovery to Create Integrated Chemistry-to-Biology Drug Discovery Platform
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement as...
June 17, 2026 | News
Agility or Corner-Cutting? Asia's Accelerated-Approval Gamble
On 1 April 2026, Japan's Pharmaceuticals and Medical Devices Agency did something no other major medicines regulator had done before it: from that date, ev...
June 16, 2026 | Analysis
PromptBio Launches Agentic AI Platform to Accelerate Scientific Discovery
The PromptBio Platform combines conversational AI with multi-agent orchestration to accelerate discovery from hypotheses to insights PromptBio, a Californ...
June 11, 2026 | News
China Approves First-in-Human Trial of Antengene’s ATG-201 for Autoimmune Diseases
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...
June 12, 2026 | News
XtalPi Lands $400M+ AI-Driven Drug Discovery Partnership for Metabolic GPCR Target
XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, announced a strategic partnership with a pro...
June 12, 2026 | News
Harbour BioMed Secures China IND Acceptance for Novel Bispecific Cancer Therapy HBM7004
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
June 12, 2026 | News
China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours
Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...
June 10, 2026 | News
Waters Launches Industry First RP Column Platform To Accelerate GLP 1 And LNP Drug Development
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottleneck...
June 10, 2026 | News
Everest Medicines Acquires Greater China Rights to Presbyopia Therapy LNZ100
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
June 09, 2026 | News
Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours
NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...
June 08, 2026 | News
Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...
June 04, 2026 | News
Ginkgo Datapoints, Tangible Scientific and Inductive Bio Launch ADME One to Accelerate Early Drug Discovery
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projec...
June 03, 2026 | News
Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia
In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...
June 02, 2026 | Analysis
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
Editor Picks
